Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc., (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.
|Details of the event are as follows:|
|Panel:||Gamma Delta CART-Cells, and “Squeezed” T-cells|
|Date:||Thursday, April 15, 2021|
|Time:||1:00 – 1:55 PM ET|
|Format:||Panel moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst|
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
Adicet Bio., Inc.
Investor and Media Contacts
Stern Investor Relations, Inc.